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E-mail address: a.mehta@dundee.ac.uk (A. Mehta)The most debilitating feature of cystic ﬁbrosis (CF) disease is uncontrolled inﬂammation of respira-
tory epithelium. The relationship between the commonest mutated form of CFTR (F508del or
DF508) and inﬂammation has not yet been elucidated. Here, we present a new paradigm suggesting
that CFTR can interact with intra-epithelial IgG, establishing a direct link between normal CFTR and
the immune system. Further, our data show that the amino-acid sequence local to F508 can bind IgG
with high afﬁnity, dependent on F508, such that loss of F508 abolishes this link both in vitro and in
the intact cell.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Introduction
Most cystic ﬁbrosis (CF) arises from a single amino-acid dele-
tion (DF508) in the cystic ﬁbrosis transmembrane conductance
regulator (CFTR, ABCC7). The resulting multi-system disease has
many unexplained features including disordered innate immunity
[1,2]. F508 is in the ﬁrst nucleotide-binding domain (NBD1) of
CFTR but no signiﬁcant structural alterations correlate with its
deletion [3]. Since the F508 region forms an accessible loop, we
speculated that this region might participate in protein–protein
interactions. We therefore looked for candidate proteins in tracheal
epithelium from DF508CFTR or CFTR-null transgenic mice [4]. Dur-
ing our control immunohistochemical studies of tracheae, we no-
ticed differential staining in the ‘non-speciﬁc’ background when
secondary anti-IgG antibodies were applied in the absence of pri-
mary. This differential distribution segregated as expected for CFTR
itself [5], suggesting that a CFTR-induced antibody-binding site
was present. CF patients are mucosally infected with a restricted
set of pathogens (see discussion) and some authors believe CF epi-
thelia are spontaneously inﬂamed in the absence of infection [6].
CF cells secrete IL-8 in excess over wild-type due to activation ofal Societies. Published by Elsevier
.NFjB [7] and IgG levels are abnormally elevated in the CF gut lu-
men [8]. The serendipitous data presented here suggest that IgG
binds to the F508 region of CFTR, F508-dependently.
2. Materials and methods
2.1. Immunohistochemistry
Wax-embedded tracheal sections from wild-type, CFTR-null or
homozygous DF508 CF mice were mounted on glass slides and
stained using diaminobenzidine [9]. HRP-labelled Protein-G
(1 lg/ml; Sigma P8170) was used to stain tissue for endogenous
IgG.
2.2. Dotblots
Peptides (10 nmol/dot) (KENIIFGVSYDEYRYRS (wild-type CFTR
peptide 503–519), KENIIGVSYDEYRYRS (DF508 CFTR peptide
503–518); SZ, GQNIHRKTTASTRK (CFTR 780–793); KE,
KEHYVDLKDRPFFA (NDPK-A 49–62); GE, GETNPADSKPGTIR
(NDPK-A 92–105)) were immobilised on nitrocellulose membranes
using a Whatman-Biometra Hybrislot suction manifold. Mem-
branes were blocked using 1% BSA then incubated with 1:1000
dilutions of HRP-labelled secondary antibodies (Sigma). AfterB.V. Open access under CC BY-NC-ND license.
Fig. 1. (A) HRP-labelled Protein-G histochemistry on tracheal sections from wild-
type, DF508 or CFTR-null mice. (B) Dotblots of KENIIF (KF), KENII (KI) and control
peptides (KE and GE) overlaid with HRP-labelled IgG. Bottom panel; autoradiograph
of I125-labelled human IgG binding to KENIIF (KF) but not KENII (KI) or control
peptides (GE, KH).
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ised using enhanced chemiluminescence. 125I-labelled puriﬁed
mouse monoclonal IgG was produced by the chloramine-T method
[10]. This IgG was repuriﬁed by gel ﬁltration; only a single iodin-
ated 150 kDa band was present after autoradiography/non-reduc-
ing SDS–PAGE.
2.3. BIAcore
Peptides were amine-coupled to a CM5 chip using standard
methods [11]. The four available channels were coupled with a
10 lM solution of either KENIIFGVSYDEYRYRS (wild-type CFTR
503–519, KENIIGVSYDEYRYRS (DF508 CFTR 503–518), GTFIKENI-
IWKGIYTYRII (Variola I6 P33002 326–344), QRVGLLGRTGSGKSTLL
(control NBD2 CFTR 1237–1253) or the ﬁnal channel was left blank
as a baseline control. Analyte was passed over each channel in this
order; the signal from the ﬁnal channel (NBD2 or blank) was auto-
matically subtracted from all other traces. IgG (10–40 lM; Sigma
I4506) was used as analyte in proprietory Biacore buffer. Biacore
software was used to calculate KD; v2 values were within pre-
scribed conﬁdence limits.
2.4. Immunoﬂuorescence
Nasal cells from patients undergoing unrelated surgery (local
ethical committee approved) were ﬁxed in 4% paraformaldehyde,
incubated in 1 mM glycine for 15 min, permeabilised using 1%
Triton X-100, washed three times in PBS, then blocked in 5% don-
key serum for 15 min. Cells were incubated in primary antibodies
(FITC-labelled anti-hIgG (Jackson) and mouse anti-CFTR NBD1
(Neomarkers, Ab-3) at 1:100) at room temperature, with shaking,
overnight. After three washes in PBS, cells were stained with rho-
damine-labelled anti-mouse IgG (Jackson, 1:100). After 2 h incuba-
tion, with shaking, the cells were washed ﬁve times in PBS and
mounted (6% n-propyl gallate, 70% glycerol, 100 mM Tris/HCl,
pH 7.4). Coverslips were sealed with nail varnish for image capture
using a Zeiss 510 laser-scanning confocal microscope.
2.5. Precipitations
Ovine tracheal epithelial membranes were prepared and
detergent-extracted as previously described [12]. A centrifuged ex-
tract was used for precipitation with protein-G Sepharose beads
(Pharmacia), i.e. the sample generated was the equivalent of the
normally-discarded ‘pre-clearing’ step applied in immunoprecipi-
tation protocols to eliminate non-speciﬁc, protein-G interactions.
Here we required these interactions to be present and used com-
petitive CFTR-peptide incubations to provide speciﬁcity. Twenty
micrograms of detergent-extracted protein was incubated with
5 ll of protein-G (or A) Sepharose bead slurry ± peptide, and
vortexed overnight at 4 C. The precipitates were washed and
phosphorylated with PKA and [c32P]-ATP to visualise CFTR protein
[13]. One unit of PKA catalytic subunit (Calbiochem–Novabiochem)
was incubated with each sample in 50 ll of 50 mM Tris–HCl (pH
7.5), 10 mM MgCl2, 100 lM unlabelled ATP, 10 lCi [c32P]-ATP
(30 C, 30 min) with vortexing. The phosphorylated beads were
subjected to SDS–PAGE and the 32P-labelled bands visualised using
a Packard InstantImager.3. Results
Tracheal staining using peroxidase-labelled protein G intensely
stained the apical membrane of wild-type mouse tracheal epithe-
lium (Fig. 1A, brown colour wild-type left panel, representative of
n = 3). Attenuated or absent membrane staining was observed atthe apical membrane of two different CFTR mutant tissues
(CFTR-null or DF508-CFTR, respectively). Aggregations of protein
G staining were observed in the null tissue (red arrows). Since
the sole difference between these epithelia was the absence
(CFTR-null) or mutation (DF508) of CFTR, these data suggest not
only that murine IgG is localised to the apical membrane in
wild-type trachea, but also that CFTR mutation can affect expres-
sion and localisation of epithelial IgG. We conﬁrmed this differen-
tial staining using secondary anti-IgG antibodies alone (not
shown).
To localise the defect, peptides were synthesised from human
CFTR local to F508, amino acids 503–516 in CFTR. These and con-
trol peptides from other parts of CFTR or unrelated proteins were
each immobilised on nitrocellulose and overlaid with different
IgG preparations. Fig. 1B shows binding of puriﬁed IgG to immobi-
lised wild-type (KF) peptide (referred to as KENIIF, where F is F508)
compared to the equivalent DF508 (KI) sequence (referred to as
KENII) and three control peptides. We found that three unrelated
peroxidase-labelled anti-IgG antibodies recognising different spe-
cies all bound speciﬁcally to KENIIF, minimally to KENII and did
not bind control peptides (Fig. 1B, top three panels). To exclude
the possibility that the interaction was with peroxidase, a pure
mouse monoclonal 125I-labelled IgG was overlaid and found to
bind wild-type KENIIF peptide (Fig. 1B, bottom panel). Thus, in
vitro, peptides corresponding to the F508 region of CFTR can bind
IgG provided F508 is present.
To quantify this in vitro interaction we applied human IgG to
the BIAcore system, which utilises surface plasmon resonance to
validate protein–protein interactions in real time. We immobilised
KENIIF, KENII or a control peptide on Biacore chips and perfused
human IgG at two different concentrations as analyte. KD was
determined to be 69 nM for the KENIIF peptide and 86 nM for
the KENII peptide (Fig. 2A). Similarity searches revealed signiﬁcant
homology between the KENIIF region of CFTR and antibody-bind-
ing domains of protein L, a bacterial virulence-related protein
[14,15].
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Fig. 3. (A) Immunoﬂuorescent staining for human IgG (FITC) and CFTR (rhodamine) u
epithelial cells (right panels). Far right panel; no primary antibody control (wild-type). S
type cells previously incubated with myristoylated (myr) KENIIF or KENII peptide. ImagProtein L interacts speciﬁcally with j light chains, whereas the
more commonly used antibody-binding proteins (A/G) both bind
the heavy chain of IgG.
We compared the binding of KENIIF, KENII and protein L to
j- and k-containing isoforms of IgG (Fig. 2B). Identical amounts
of total human IgG or three isoforms of IgG were immobilised on
96-well plates and screened for biotinylated peptide binding.
s 583 (2009) 2493–2499 2495peptides. (A) Bottom, BIAcore traces for binding of human IgG (10 nM, analyte) to
tein L to immobilised isoforms of IgG and IgA.
sing either wild-type (left panels) or homozygous DF508 primary ciliated nasal
cale bar, 5 lM. Images are representative of n = 4 experiments. (B) As in A but wild-
es are representative of results from three different experiments.
Fig. 4. (A) Autoradiograph showing precipitations from detergent extract of sheep tracheal membranes. Lanes from left: PG, protein G beads alone; +KF, addition of 10 lM
KENIIF; +KI, addition of 10 lM KENII; +GE addition of 10 lM control peptide; NM, no membranes; PKA, PKA alone; ProtA, precipitation with protein A. CFTR and PKA are
indicated by arrows. (B) BIAcore trace for human IgG (40 nM, analyte) binding to immobilised I6 peptide compared to KENIIF and KENII.
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KENII showed a signiﬁcantly reduced interaction, whereas IgA
bound KENIIF, KENII and protein L with equal efﬁcacy. Protein L
bound IgG containing the j (but not k) light chain as expected.
These data conﬁrm that KENIIF peptide can bind IgG and that
F508 regulates binding. Further work will have to establish the
number of sites where this interaction takes place but judging by
our recent experience with the complex interaction of the multi-
meric protein kinase CK2 with the very same KENIIF region of
CFTR, this is likely to involve more than just one motif on the inter-
acting protein [16]. Our working hypothesis is that this region can
adopt more than one conformation.
Next, we investigated whether IgG localises with CFTR in vivo
using immunoﬂuorescence and laser-scanning confocal micros-
copy. We stained wild-type human ciliated airway cell biopsies
[17] with anti-human IgG (FITC-label) and anti-human CFTR
(rhodamine-label). Fig. 3A shows that CFTR and IgG staining colo-
calises speciﬁcally at the ciliated apical membrane of wild-type
cells. Staining for both proteins was absent in cells from three
DF508/DF508 CF patients. To determine whether the F508 region
is responsible for the observed colocalisation, we attempted com-
petition with cell-permeant KENIIF/KENII CFTR peptides. KENIIF
and KENII peptides were myristoylated (myr-) and the ciliated cells
were incubated in the presence of 10 lM peptide for 4 h prior toﬁxation and staining. Incubation with myr-KENIIF (but not myr-
KENII) peptide abolished the colocalisation (Fig. 3B).
We theorised that, if CFTR is bound to IgG in vivo, protein-G
Sepharose should coprecipitate IgG and CFTR from epithelial mem-
brane extracts without needing an antibody to CFTR. Protein-G
precipitation from sheep tracheal membrane extract [18] pulled
down a PKA-phosphorylatable band at the molecular weight of
CFTR that was not present in an identical protein-A precipitate
(Fig. 4A). Since protein G binds ovine IgG, but protein A does not
bind as efﬁciently, the simplest interpretation was that the phos-
phorylatable band interacted with an endogenous, ovine, mem-
brane-associated IgG. Again, the protein G interaction was
inhibitable with KENIIF, but not KENII or another peptide, specify-
ing the interaction to this region (Fig. 4A). These experiments also
conﬁrmed that the interaction is with endogenous antibody and
not an artefact of the tagged antibodies. Thus, across mouse, sheep
and human airway epithelia, the data consistently suggest that
CFTR can bind IgG. The similarity between CFTR and protein L sug-
gests that these IgG-binding molecules may have a similar mode of
interaction.
Protein L is not the only molecule having sequence homology
with this KENIIF region; Fig. 5 shows that certain pathogenic bac-
terial proteins also contain related sequences; we noticed a strik-
ing similarity in a poxviral protein (I6, below, and Fig. 6).
Fig. 5. Alignment of multiple protein sequences from pathogenic organisms that bear similarity to the F508 region of CFTR.
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(Variola I6, P33002 326–342) and tested it for interaction with
IgG using BIAcore. Fig. 4B shows that the IgG interaction with Vari-
ola I6 peptide was the strongest we had tested.
4. Discussion
Our studies have produced unexpected results that relate to the
pathway betweenDF508 and the disordered immunity responsible
for most CF morbidity. The combined data point to an antibody-
binding site in CFTR and suggest that CFTR’s F508 status may affect
apical localisation of IgG. Our data demonstrate, by several inde-
pendent methods, an F508-dependent interaction between CFTR
and IgG. We have shown that the interaction is direct using
BIAcore, and can occur in vivo because IgG both colocalises and
coprecipitates with CFTR. Furthermore, the binding can be dis-
rupted by exogenous KENIIF (but not KENII) peptide, strengthening
the conclusion that this pathogenic region of CFTR binds IgG.
Apically-localised IgG provides a ﬁrst line of defence against
respiratory infections and our data suggest that this immune mol-
ecule is missing in most cystic ﬁbrosis. Protein G, which binds IgG,
is made by staphylococci to evade the immune response and nearly
all CF babies develop Staphylococcus infection immediately after
birth for unknown reasons. Mucosal inﬂammation may be hyper-
active in CF to compensate for the missing IgG defence. Such a
hyperactive compensation might also be present in heterozygotes
giving them an advantage in resistance to epithelial infections.
Interestingly, Fig. 5 shows that many infectious organisms contain
similar sequences; one has been identiﬁed as a virulence factor. Aprotein kinase (CK2) known to regulate viral life cycles also inter-
acts with NBD1 in an F508-dependent manner [16] and it may be
that a complex interaction with multiple regulators of immunity
occurs at this site which might relate to the locally restricted types
of infections found in CF epithelia.
We speculate that the presence of an avid IgG-binding peptide
in a virulent pathogen like smallpox suggests that it may have
evolved this generic IgG-binding capacity either in order to seques-
ter the epithelial immune mechanism or to harness it in some way
to its own advantage. We were led to this speculation by epidemi-
ological studies evaluating HIV-resistance genes (CCR5-D32) which
are reported to be selectively ampliﬁed by smallpox outbreaks on a
similar timescale and population frequency to DF508 [19]. These
authors write; ‘Frequency of [CCR5-D32] is estimated . . . 10% in
European populations. The allele is virtually absent in African,
Asian, Middle Eastern, and American Indian populations. . .The geo-
graphic distribution . . . also implicates smallpox as the most likely
historical source of selection . . . Scandinavian populations . . . were
hit particularly hard by intense smallpox epidemics. Frequency of
the CCR5-D32 variant forms a north-to-south [de]cline. . .with
greatest prevalence in Scandinavian countries’. The frequency of
the DF508 mutation follows an almost identical pattern and thus
could be due to the same selective pressures [20]. This raises the
possibility that the prevalence of CF is due to the greater survival
of persons heterozygous for DF508 during smallpox epidemics,
wherein childhood mortality reached 80%. Although the mecha-
nism is unclear, we note that I6 is important in viral replication
and viral capsid ﬁlling with viral DNA [21]; our observation that
I6 can bind IgG additionally relates I6 to the host immune re-
sponse, possibly using a similar mechanism to the organisms listed
in Fig. 5. Further work is needed to establish exactly how this
mechanism functions.
We do not yet know which sites within IgG bind to the peptides
reported here but it is becoming clear that this region of CFTR is on
the surface of the nucleotide-binding domain where it is accessible
Fig. 6. Alignment of the KENIIW region of I6 from various poxviruses to illustrate conservation of the CFTR-like sequence.
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interaction is interesting from a CF perspective. We suggest cau-
tion in interpretation of results from CFTR experiments that use
antibodies, particularly from native epithelial tissues. For example,
pre-clearing immunoprecipitations using protein G alone might
discard a population of CFTR molecules of biological importance.
Our data also add a potential caveat to trafﬁcking therapies for
DF508-CFTR. Such treatments may not restore IgG binding. Two
decades after the discovery of CFTR, the mechanism responsible
for CF disease remains disputed with some stating that ‘CF is an
ion channel disease’ and others claiming that ‘CF is a disorder of
immunity involving a restricted set of pathogens’. Our contribution
is to highlight that the CFTR peptide sequence straddling the site of
the commonest (by far) mutation around F508 bears striking sim-
ilarities with a range of pathogen proteins. We hope that our stud-
ies into the diverse in vitro [16] and more recent in vivo [22]
functions manifested by such peptides will fuel the debate on CF
pathogenesis. Currently, there are three recognised ‘i’ factors in
CF: ions, inﬂammation and immunity to which we now add a
fourth, immunoglobulin. The latter is missing in most CF and we
now need to determine the consequences for the patient.Acknowledgements
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